Researchers at Renal Week 2010 in Denver have reported on what they believe is the first prospective, randomized study to show that targeting a serum hemoglobin (Hb) level of 13 g/dL or higher has a renoprotective effect in kidney transplant patients.
Most renal transplant recipients may not benefit from being vaccinated against the H1N1 influenza virus, according to a new German study presented at Renal Week 2010 in Denver.
New data presented at Renal Week 2010 in Denver confirm the high morbidity and mortality associated with secondary hyperparathyroidism (SHPT) in dialysis patients, emphasizing the need for early referral as well as other therapeutic interventions.
A high phosphocalcic product significantly increases the risk of non- eligibility for a kidney transplant among adults with end-stage renal disease (ESRD), Canadian researchers concluded in a study presented at Renal Week 2010 in Denver.
Oral paricalcitol (OP) appears to have similar efficacy and safety compared with oral calcitriol (OC) in dialysis patients with secondary hyperparathyroidism (SHPT), according to results from a randomized, controlled trial presented at Renal Week 2010 in Denver.
High baseline serum phosphorus levels in CKD patients may predict an increased likelihood of renal disease progression and death, according to Italian investigators, who presented their findings at Renal Week 2010 in Denver.
Cinacalcet is a safe and effective option for treating hypocalcemia and secondary hyperparathyroidism (SHPT) in renal transplant recipients, according to a new German study presented at Renal Week 2010 in Denver.
A significant proportion of patients with CKD but not on dialysis (CKD-NOD) with new-onset moderately severe anemia do not receive treatment with iron or erythropoiesis-stimulating agents (ESAs), suggest study findings presented at Renal Week 2010 in Denver.
Pomegranate juice may ward off a number of complications in dialysis patients.
Angiotensin receptor blocker (ARB) treatment may affect response to erythropoiesis-stimulating agents (ESAs) in hemodialysis (HD) patients by disturbing iron homeostasis, Japanese researchers reported at Renal Week 2010 in Denver.
Please login or register first to view this content.
